Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara Ebola Zaire (MVA EBOZ) as a prime-boost to GSK's Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate.

The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).

Read more